Direct compression for amidopyrine veterinary tablets is selected only after pre-compression flowability and thermal softening risk are reconciled. The API, CAS 58-15-1, is a pyrazolone derivative with a melting point of 107–109 °C, which places an upper boundary on compression heat. A model starting blend for a 250 mg amidopyrine tablet with target tablet weight 800 mg comprises 31.25% w/w amidopyrine, 40.00% w/w microcrystalline cellulose, 24.75% w/w lactose monohydrate, 3.00% w/w crospovidone, and 1.00% w/w magnesium stearate. The API is screened through an 800 µm stainless-steel sieve before mixing to remove agglomerates; batches with bulk density below 0.45 g/cm³ are recalibrated because low bulk density increases segregation potential in the tablet press hopper. Powder flow is measured with a Hosokawa Powder Characteristics Tester; formulations with Hausner ratio above 1.35 or Carr Index above 25% are rejected for direct compression and diverted to dry granulation. Compression studies on a 16-station rotary press equipped with 9 mm biconvex tooling indicate that compression force must remain within 8–14 kN; below 8 kN tablet breaking force falls below 50 N, and above 14 kN local die-wall friction at the low-melting amidopyrine particles can generate enough heat to initiate surface adhesion and picking. Tablet breaking force is measured per Ph. Eur. 2.9.8, friability per Ph. Eur. 2.9.7, and disintegration per Ph. Eur. 2.9.1; production lots are released when friability is ≤ 1.0% and disintegration time is ≤ 15 min in 900 mL water at 37 ± 2 °C. Content uniformity follows Ph. Eur. 2.9.40 or USP <905> with acceptance value ≤ 15.0. Tablet film coating, if applied, uses an aqueous ready-to-disperse system at 2–3% w/w weight gain; process exhaust temperature is kept below 45 °C to avoid surface softening of the low-melting API. Because amidopyrine has been removed from human pharmacopoeias in multiple jurisdictions, the veterinary dosage form must be evaluated against the specific national monograph or licensed veterinary medicinal product specification before manufacture; absence of a current monograph does not exempt the site from full release testing.

When Amidopyrine Veterinary API Is Processed into Injectable Solutions

For injectable presentations, amidopyrine is dissolved in water for injection at a concentration range from 100 mg/mL to 250 mg/mL; dissolution is temperature-assisted to 35–40 °C, and the solution is adjusted to pH 5.5–6.5 using dilute hydrochloric acid or sodium hydroxide. Carbon dioxide can reduce pH drift; therefore, nitrogen sparging before filling is used, with residual oxygen in headspace controlled to ≤ 2.0% v/v. Oxidative degradation of the pyrazolone ring is accelerated by metal ions such as Fe³⁺ and Cu²⁺; disodium edetate at 0.01–0.05% w/v and sodium metabisulfite at 0.10–0.20% w/v are evaluated only when stability data indicate discolouration. Non-sterile bulk solution is filtered sequentially through 0.45 µm and 0.22 µm membrane filters, then filled under Grade A aseptic conditions. If terminal steam sterilisation is considered, the thermal cycle at 121 °C for 15 min must be supported by degradation profiles; published data for this specific configuration is limited, and an aseptic filtration route is preferred unless the marketing authorisation explicitly validates terminal sterilisation. Sterility testing follows Ph. Eur. 2.6.1, bacterial endotoxin testing follows Ph. Eur. 2.6.14, and particulate contamination is controlled per Ph. Eur. 2.9.19 or USP <788>. The finished injection is protected from light because ultraviolet exposure promotes photolytic discolouration; storage is specified at 15–25 °C unless stability protocols justify broader excursions. Batch records must note that amidopyrine is incompatible with strong oxidising agents and with copper or brass contact surfaces in the filling line; stainless steel 316L remains the preferred product-contact material.

At low amidopyrine doses in capsule filling, fill weight drift is governed by particle size mismatch between the API and lactose carrier. A starting formula for a 25 mg amidopyrine capsule with a 100 mg fill weight includes 25.0% w/w amidopyrine, 63.0% w/w lactose monohydrate, 10.0% w/w maize starch, 1.5% w/w croscarmellose sodium, and 0.5% w/w magnesium stearate. The API is first triturated with an equal portion of lactose passed through a 250 µm sieve to form a uniform premix; this step reduces dose-strength variability because aminopyrine has a needle-like crystal habit that resists uniform distribution at low loadings. Capsule filling on a tamping-pin machine requires powder bed height control and pin compression settings to avoid weight variation above ± 3.0%; the blend is granulated by slugging if Carr Index exceeds 25%. Fill weight uniformity is tested on both empty and filled capsules; net fill weight is measured from 20 capsules, and individual weights must fall within ± 5.0% of mean unless justified by the formula. Content uniformity is evaluated per Ph. Eur. 2.9.6 or USP <905> using a stratified sampling plan. The gelatin or HPMC capsule shell must have moisture specification ≤ 12.0% w/w at release, because amidopyrine blends can absorb moisture and yield brittle shells if stored above 60% relative humidity. Dissolution testing is carried out using apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid at 37 ± 0.5 °C, with the Q value set by the veterinary marketing authorisation; no universal compendial dissolution monograph may exist in markets where aminopyrine is only veterinary-approved. Over-lubrication with magnesium stearate above 1.0% w/w delays disintegration and dissolution; therefore, blending time after lubricant addition is limited to 3–5 min in a diffusion blender rotating at 25 rpm.

When amidopyrine is formulated as a dry powder for in-feed or drinking-water administration, the pure API is active at low mass and direct handling of concentrated powder creates dust exposure. The standard carrier is spray-dried lactose monohydrate or glucose monohydrate with D50 in the range 150–250 µm; amidopyrine is pre-micronized or air-jet milled to D90 ≤ 75 µm before geometric dilution. A typical top-dress powder contains amidopyrine at 5.0% w/w, but concentrations are customised downward to 1.0% w/w for small-animal dosing because dosing cup precision improves with larger carrier mass. The powder is blended in a 300 L ribbon blender at 60% working volume for 20 min after initial pass-through of agglomerates; residual moisture after blending is controlled to ≤ 2.0% w/w to prevent caking in sachets. Powder flow is characterised by flowability through a 10 mm orifice; mass flow rate is recorded but is not a release parameter. Homogeneity is assessed by taking 10 samples across the blender using a sampling thief; assay values relative to label must lie within 90.0–110.0% with relative standard deviation ≤ 5.0%. The final powder is filled into foil-lined sachets under relative humidity ≤ 40%; heat-sealing temperature is maintained at 110–130 °C to avoid melting the low-melting-point API near the seal area. Cross-contamination risk in multi-product facilities is substantial because amidopyrine adheres to plastic surfaces and baffles; cleaning validation uses swab limits calculated from a carryover criterion of ≤ 10 ppm into the next product unless a stricter veterinary residue limit applies.

Wet Granulation Endpoint Shift Caused by Amidopyrine Solubility in Binder Systems

In high-dose non-segregating formulations, wet granulation of amidopyrine is not a default route because the API dissolves partially in water-based binder solutions and recrystallises upon drying, producing hard granules with slow disintegration. When wet granulation is unavoidable, a hydroalcoholic granulating fluid consisting of isopropanol and purified water at 80:20 v/v saturated with povidone K30 at 5.0% w/w is used; water is kept as low as possible to limit API dissolution. The powder bed is pre-blended in a high-shear mixer, then granulating fluid is added at 0.8–1.2 L/min per 100 kg of powder. Granulation endpoint is determined by impeller power consumption curve leveling and by target granule size distribution with 70% w/w retained between 250 µm and 850 µm. Wet mass is dried in a fluid-bed dryer with inlet air temperature 50–60 °C and product temperature not exceeding 40 °C; loss on drying is monitored at 105 °C until ≤ 1.5% w/w. After dry milling through a 1.0 mm screen, granules are blended with crospovidone and magnesium stearate. Tablets from this granulation route show lower compressibility than direct compression formulations; tablet hardness at 12 kN may be 40–60 N, and disintegration time frequently exceeds 15 min if granule density exceeds 1.35 g/cm³. A more robust alternative for water-sensitive blends is dry granulation by roller compaction with roll pressure 20–40 kN and screen size 0.8 mm; this avoids API dissolution entirely. The production decision between wet and dry granulation is made only after a compatibility study across excipient lots, because variability in hygroscopicity of maize starch and povidone changes endpoint from batch to batch. Granule dissolution is tested per Ph. Eur. 2.9.3 unless the veterinary monograph specifies apparatus and acceptance criteria.

Does Amidopyrine Remain Homogeneous in Extended-Feed Premixes?

For medicated feed premixes, homogeneity is determined less by total mixing time than by carrier particle geometry, electrostatic charge, and moisture. A typical final premix contains amidopyrine at 1.0% w/w adsorbed onto solvent-extracted soybean meal or mineral carrier with oil addition at 1–2% w/w to reduce segregation. The geometric dilution sequence begins with a 1:10 preblend of API and carrier in a planetary mixer for 10 min, then expands to 1:100 in a horizontal double-ribbon blender for 20 min, and finally adjusts to 1:1000 in a paddle mixer for 15 min. The carrier is sieved through 630 µm; particles below 125 µm are minimized because fine particles promote dust and segregation. Moisture content before packaging is limited to ≤ 12.0% w/w for vegetable carriers and ≤ 6.0% w/w for mineral carriers to prevent caking and microbial risk. The final premix is filled into multi-wall paper sacks with polyethylene liner, and each batch is passed through a sieving step of 1.0 mm to remove agglomerates. Cross-contamination is managed by dedicating or sequencing premix lines; observed batch-to-batch variance in amidopyrine assay depends heavily on whether the previous product contained sticky carriers such as molasses-based premixes. Cold-mix operations at below 5 °C are avoided because electrostatic charge on the API increases and wall adhesion causes low assay in the first discharge fraction.

Aminopyrine Oral Solutions Under Oxidative Stress and pH Drift

When preparing concentrated oral solutions for drinking-water medication, amidopyrine is dissolved as a stock solution that is later diluted in the target species’ water supply. The concentrated solution is often specified at 200 mg/mL amidopyrine in purified water with sodium benzoate or potassium sorbate as preservative at 0.10–0.20% w/v, a chelator such as disodium edetate at 0.005–0.010% w/v, and a buffer system to maintain pH 5.5–6.5. Oxidation of the pyrazolone ring is the principal stability risk; oxidative degradation produces yellow discolouration, and the rate increases above pH 7.0 and upon exposure to ultraviolet light. Amber polyethylene terephthalate or Type III glass containers with light transmission below 10% at 420 nm are used. Nitrogen headspace sparging or vacuum-capping reduces dissolved oxygen to ≤ 2.0 mg/L. If sodium metabisulfite is used at 0.05% w/v, compatibility with amidopyrine must be confirmed, because sulfite adduct formation may occur under certain conditions. The solution is filtered through a 5 µm clarifying filter before filling; terminal sterile filtration is not required for oral solutions, but microbial limits follow Ph. Eur. 5.1.4 or the national equivalent. Filling lines with copper-containing fittings are not used; stainless steel 316L and food-grade EPDM seals are specified. Storage is defined at 15–25 °C in the dark; freeze-thaw cycling below 0 °C can cause precipitation of preservatives rather than amidopyrine, but the dissolution step must still be verified visually and by assay after thawing. Dose marking on the primary container indicates the concentration of amidopyrine base, not salt form; certificates of analysis must list assay on both as-is and dried basis.